Adagene (ADAG) Total Non-Current Liabilities (2019 - 2026)
Adagene (ADAG) posted quarterly Total Non-Current Liabilities of -$205.1 billion for Q4 2025, down 529515.03% year-over-year from N/an in Q4 2024, and down 717177.32% quarter-over-quarter from $28.6 million in Q2 2025.
Adagene (ADAG) Total Non-Current Liabilities (2019 - 2026) Analysis & Trends
Adagene (ADAG) has reported Total Non-Current Liabilities for 7 consecutive years, with -$205.1 billion the latest figure, recorded in Q4 2025.
- In Q4 2025, Total Non-Current Liabilities fell 529515.03% year-over-year to -$205.1 billion; the TTM figure through Dec 2025 stood at -$205.1 billion (down 529515.03% YoY), while the FY2025 annual figure was -$205.1 billion, down 529515.03% from the prior year.
- Total Non-Current Liabilities eased to -$205.1 billion in Q4 2025 per ADAG's latest filing, from $28.6 million in the prior quarter.
- Across five years, Total Non-Current Liabilities topped out at $45.2 million in Q4 2023 and bottomed at -$205.1 billion in Q4 2025.
- Historically, Total Non-Current Liabilities has averaged -$29.1 billion across 5 years, with a median of $30.1 million in 2021.
- Annual changes were most pronounced in 2024 — Total Non-Current Liabilities surged 100.16% — and 2025, when it slumped 529515.03%.
- Adagene's Total Non-Current Liabilities stood at $32.9 million in 2021, then slumped by 87289.64% to -$28.6 billion in 2022, then surged by 100.16% to $45.2 million in 2023, then fell by 14.22% to $38.7 million in 2024, then plunged by 529515.03% to -$205.1 billion in 2025.
- Business Quant data shows ADAG's Total Non-Current Liabilities at -$205.1 billion in Q4 2025, $28.6 million in Q2 2025, and $38.7 million in Q4 2024.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Non-Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 5.92 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 7.74 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 40.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 1.53 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 1.88 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | - |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 9.32 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 4.20 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 1.17 Bn |
| 10 | Adagene | 310.54 Mn | 310.54 Mn | - | 26.39 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 26.39 Mn |
| Dec 31, 2025 | -205.12 Bn |
| Jun 30, 2025 | 28.60 Mn |
| Dec 31, 2024 | 38.74 Mn |
| Jun 30, 2024 | 44.19 Mn |
| Dec 31, 2023 | 45.17 Mn |
| Jun 30, 2023 | -27.68 Bn |
| Dec 31, 2022 | -28.65 Bn |
| Jun 30, 2022 | -29.80 Bn |
| Dec 31, 2021 | 32.86 Mn |
| Jun 30, 2021 | 31.58 Mn |
| Dec 31, 2020 | 19.11 Mn |
| Dec 31, 2019 | 8.70 Mn |